Entrar/Registro  
INICIO ENGLISH
 
NCT Neumología y Cirugía de Tórax
   
MENÚ

Contenido por año, Vol. y Num.

Índice de este artículo

Información General

Instrucciones para Autores

Mensajes al Editor

Directorio






>Revistas >NCT Neumología y Cirugía de Tórax >Año 2016, No. 1


Mejía M, Buendía-Roldan I, Mateos-Toledo H, Estrada A, Espinoza-Hernández M, Juárez-Hernández F, Vargas-Domínguez C, Selman M
Primer Consenso Mexicano sobre Fibrosis Pulmonar Idiopática
Neumol Cir Torax 2016; 75 (1)

Idioma: Español
Referencias bibliográficas: 96
Paginas: 32-51
Archivo PDF: 1826.33 Kb.

[Texto completo - PDF]

FRAGMENTO

La enfermedad pulmonar intersticial (EPI) en ausencia de algún proceso infeccioso y/o neoplásico engloba varios trastornos respiratorios, los cuales tienen presentación clínica variable (aguda, subaguda o crónica). Debido a que son entidades con histologías diferentes, cursan con diferentes grados de inflamación y fibrosis que al progresar muestran rasgos cicatrizales variables donde el pulmón terminal es el resultado final de esta progresión, perdiendo sus características específicas, lo que imposibilita diferenciarlas en forma adecuada.


Palabras clave: Fibrosis pulmonar idiopática, tomografía computada de alta resolución, neumonía intersticial usual, discusión multidisciplinaria.


REFERENCIAS

  1. Wells AU. Managing diagnostic procedures in idiopathic pulmonary fibrosis. Eur Respir Rev 2013;22(128):158-162. doi: 10.1183/09059180.00001213.

  2. Travis WD, Costabel U, Hansell DM, et al.; ATS/ERS Committee on Idiopathic Interstitial Pneumonias. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013;188(6):733-748. doi: 10.1164/rccm.201308-1483ST.

  3. Raghu G, Collard HR, Egan JJ, et al.; ATS/ERS/JRS/ ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183(6):788-824. doi: 10.1164/rccm.2009-040GL.

  4. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;183(4):431-440. doi: 10.1164/ rccm.201006-0894CI.

  5. Bjoraker JA, Ryu JH, Edwin MK, et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998;157(1):199-203.

  6. Coultas DB, Hughes MP. Accuracy of mortality data for interstitial lung diseases in New Mexico, USA. Thorax 1996;51(7):717-720.

  7. Karakatsani A, Papakosta D, Rapti A, et al.; Hellenic Interstitial Lung Diseases Group. Epidemiology of interstitial lung diseases in Greece. Respir Med 2009;103(8):1122- 1129. doi: 10.1016/j.rmed.2009.03.001.

  8. Thomeer MJ, Costabe U, Rizzato G, Poletti V, Demedts M. Comparison of registries of interstitial lung diseases in three European countries. Eur Respir J Suppl 2001;32:114s-118s.

  9. Coultas DB, Zumwalt RE, Black WC, Sobonya RE. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med 1994;150(4):967-972.

  10. Curbelo P. Encuesta de EPID en Latinoamérica–ALAT 2013. Respirar 2013;5: 5-8.

  11. Raghu G, Chen SY, Yeh WS, et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11. Lancet Respir Med 2014;2(7):566-572. doi: 10.1016/ S2213-2600(14)70101-8.

  12. Fernández Pérez ER, Daniels CE, Schroeder DR, et al. Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study. Chest 2010;137(1):129-137. doi: 10.1378/chest.09-1002.

  13. Von Plessen C, Grinde O, Gulsvik A. Incidence and prevalence of cryptogenic fibrosing alveolitis in a Norwegian community. Respir Med 2003;97(4):428-435.

  14. Gribbin J, Hubbard RB, Le Jeune I, Smith CJ, West J, Tata LJ. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax 2006;61(11):980-985.

  15. Caminati A, Madotto F, Cesana G, Conti S, Harari S. Epidemiological studies in idiopathic pulmonary fibrosis: pitfalls in methodologies and data interpretation. Eur Respir Rev 2015; 24(137):436-444. doi: 10.1183/16000617.0040-2015.

  16. Ley B, Collard HR. Epidemiology of idiopathic pulmonary fibrosis. Clin Epidemiol 2013;5:483-492. doi: 10.2147/ CLEP.S54815.

  17. Navaratnam V, Fleming KM, West J, et al. The rising incidence of idiopathic pulmonary fibrosis in the UK. Thorax 2011;66(6):462-467. doi: 10.1136/thx.2010.148031.

  18. Xaubet A, Ancochea J, Bollo E, et al.; Sociedad Española de Neumología y Cirugía Torácica (SEPAR) Research Group on Diffuse Pulmonary Diseases. Guidelines for the diagnosis and treatment of idiopathic pulmonary fibrosis. Sociedad Española de Neumología y Cirugía Torácica (SEPAR) Research Group on Diffuse Pulmonary Diseases. Arch Bronconeumol 2013;49(8):343-353. doi: 10.1016/j.arbres. 2013.03.011.

  19. King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet 2011; 378(9807):1949-1961. doi: 10.1016/ S0140-6736(11)60052-4.

  20. Xaubet A, Ancochea J, Blanquer R, et al.; Grupo de Investigación en Enfermedades Pulmonares Intersticiales Difusas. Área de Técnicas y Transplante. SEPAR. Diagnóstico y tratamiento de las enfermedades pulmonares intersticiales difusas. Arch Bronconeumol 2003; 39(12):580-600.

  21. Barreto-Rodríguez JO, Mejía M, Buendía-Roldán I. Panorama actual de la fibrosis pulmonar idiopática en México. Neumol Cir Torax 2015;74(4):256-261.

  22. Selman M, Carrillo G, Estrada A, et al. Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern. PLos ONE 2007; 2(5):e482

  23. American Thoracic Society Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000;161(2 Pt 1):646-664.

  24. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;183(4):431-440. doi: 10.1164/ rccm.201006-0894CI.

  25. García-Sancho Figueroa MC, Carrillo G, Pérez-Padilla R, et al. Risk factors for idiopathic pulmonary fibrosis in a Mexican population. A case-control study. Respir Med 2010;104(2):305-309. doi: 10.1016/j.rmed.2009.08.013

  26. García-Sancho MC, Buendía-Roldán I, Fernández-Plata MR, et al. Familial pulmonary fibrosis is the strongest risk factor for idiopathic pulmonary fibrosis. Respir Med 2011;105(12):1902-1907. doi: 10.1016/j. rmed.2011.08.022.

  27. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell 2013;153(6):1194- 1217. doi: 10.1016/j.cell.2013.05.039.

  28. Selman M, Pardo A. Revealing the pathogenic and aging-related mechanisms of the enigmatic idiopathic pulmonary fibrosis. An integral model. Am J Respir Crit Care Med 2014;189(10):1161-1172. doi: 10.1164/ rccm.201312-2221PP.

  29. Raghu G, Rochwerg B, Zhang Y, et al.; American Thoracic Society; European Respiratory society; Japanese Respiratory Society; Latin American Thoracic Association. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med 2015;192(2):e3–e19 doi: 10.1164/ rccm.201506-1063ST.

  30. Katzenstein AL, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med 1998;157(4 Pt 1):1301-1315.

  31. Sverzellati N. Highlights of HRCT imaging in IPF. Respir Res 2013;14 Suppl 1:S3. doi: 10.1186/1465-9921-14-S1-S3.

  32. Lynch DA, Godwin JD, Safrin S, et al.; Idiopathic Pulmonary Fibrosis Study Group. High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am J Respir Crit Care Med 2005;172(4):488-493.

  33. Sundaram B, Gross BH, Martinez FJ, Oh E, et al. Accuracy of high-resolution CT in the diagnosis of diffuse lung disease: effect of predominance and distribution of findings. AJR Am J Roentgenol 2008;191(4):1032-1039. doi: 10.2214/AJR.07.3177.

  34. Wells AU. The revised ATS/ERS/JRS/ALAT diagnostic criteria for idiopathic pulmonary fibrosis (IPF)--practical implications. Respir Res 2013;14 Suppl 1:S2. doi: 10.1186/1465-9921-14-S1-S2.

  35. Hodnett PA, Naidich DP. Fibrosing interstitial lung disease. A practical high-resolution computed tomography- based approach to diagnosis and management and a review of the literature. Am J Respir Crit Care Med 2013;188(2):141-149. doi: 10.1164/rccm.201208-1544CI.

  36. Wuyts WA, Cavazza A, Rossi G, Bonella F, Sverzellati N, Spagnolo P. Differential diagnosis of usual interstitial pneumonia: when is it truly idiopathic? Eur Respir Rev 2014;23(133):308-319. doi: 10.1183/09059180.00004914.

  37. Meyer KC, Raghu G, Baughman RP, et al.; American Thoracic Society Committee on BAL in Interstitial Lung Disease. An Official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med 2012;185(9):1004-1014. doi: 10.1164/rccm.201202-0320ST.

  38. Ohshimo S, Bonella F, Cui A, et al. Significance of bronchoalveolar lavage for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009;179(11):1043- 1047. doi: 10.1164/rccm.200808-1313OC.

  39. Morell F, Villar A, Montero MA, et al. Chronic hypersensitivity pneumonitis in patients diagnosed with idiopathic pulmonary fibrosis: a prospective case-cohort study. Lancet Respir Med 2013;1(9):685-694. doi: 10.1016/ S2213-2600(13)70191-7.

  40. Babiak A, Hetzel J, Krishna G, et al. Transbronchial cryobiopsy: a new tool for lung biopsies. Respiration 2009;78(2):203-208. doi: 10.1159/000203987.

  41. Fischer A, Antoniou KM, Brown KK, et al.; ERS/ATS Task Force on Undifferentiated Forms of CTD-ILD. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J 2015;46(4):976-987. doi: 10.1183/13993003.00150-2015.

  42. Moua T, Zamora Martínez AC, Baqir M, Vassallo R, Limper AH, Ryu JH. Predictors of diagnosis and survival in idiopathic pulmonary fibrosis and connective tissue disease-related usual interstitial pneumonia. Respir Res 2014;15:154. doi: 10.1186/s12931-014-0154-6.

  43. Papanikolaou I, Drakopanagiotakis F, Polychronopoulos VS. Acute exacerbations of interstitial lung diseases. Curr Opin Pulm Med 2010;16(5): 480-486. doi: 10.1097/ MCP.0b013e32833ae49d.

  44. Song JW, Hong SB, Lim CM, Koh Y, Kim DS. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J 2011; 37(2):356-363. doi: 10.1183/09031936.00159709.

  45. Collard HR, Moore BB, Flaherty KR, et al.; Idiopathic Pulmonary Fibrosis Clinical Research Network Investigators. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007;176(7):636-643.

  46. Judge EP, Fabre A, Admali HI, Egan JJ. Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Eur Respir J 2012; 40(1):93- 100 doi: 10.1183/09031936.00115511.

  47. Antoniou KA, Wells AU. Acute exacerbation of idiopathic pulmonary fibrosis. Respiration 2013;86(4):265-274. doi: 10.1159/000355485.

  48. Schmidt SL, Nambiar AM, Tayob N, et al. Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema. Eur Respir J 2011;38(1):176-183. doi: 10.1183/09031936.00114010.

  49. Ryerson CJ, Hartman T, Elicker BM, et al. Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis. Chest 2013;144(1):234-240. doi: 10.1378/chest.12-2403.

  50. Kitaguchi Y, Fujimoto K, Hanaoka M, Kawakami S, Honda T, Kubo K. Clinical characteristics of combined pulmonary fibrosis and emphysema. Respirology 2010;15(2):265- 271. doi: 10.1111/j.1440-1843.2009.01676.x.

  51. Cottin V, Nunes H, Brillet PY, et al; Groupe d’Étude et de Recherche sur les Maladies Orphelines Pulmonaires (GERM O P). Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J 2005;26(4): 586-593.

  52. Mejía M, Carrillo G, Rojas-Serrano J, et al. Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. Chest 2009;136(1):10-15. doi: 10.1378/chest.08-2306.

  53. Nathan SD, Noble PW, Tuder RM. Idiopathic pulmonary fibrosis and pulmonary hypertension: connecting the dots. Am J Respir Crit Care Med 2007;175(9):875-880.

  54. Proceedings of the 4th World Symposium on Pulmonary Hypertension, February 2008, Dana Point, California, USA. J Am Coll Cardiol 2009;54(1 Suppl):S1-S117.

  55. Seeger W, Adir Y, Barberà JA, et al. Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol 2013;62(25 Suppl):D109-D116. doi: 10.1016/j. jacc.2013.10.036.

  56. Han MK, Bach DS, Hagan PG, et al.; IPFnet Investigators. Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction. Chest 2013;143(6):1699-1708. doi: 10.1378/ chest.12-1594.

  57. Zimmermann GS, von Wulffen W, Huppmann P, et al. Haemodynamic changes in pulmonary hypertension in patients with interstitial lung disease treated with PDE-5 inhibitors. Respirology 2014;19(5):700-706. doi: 10.1111/resp.12294.

  58. Onda N, Tanaka Y, Hino M, Gemma A. Bosentan for pulmonary hypertension secondary to idiopathic pulmonary fibrosis. Respir Med Case Rep 2014;14:19-23. doi: 10.1016/j.rmcr.2014.11.008.

  59. Hallowell RW, Reed RM, Fraig M, Horton MR, Girgis RE. Severe pulmonary hypertension in idiopathic nonspecific interstitial pneumonia. Pulm Circ 2012; 2(1):101-106. doi: 10.4103/2045-8932.94842.

  60. Hubbard R, Venn A, Lewis S, Britton J. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am J Respir Crit Care Med 2000; 16181):5-8.

  61. Tomassetti S, Gurioli C, Ryu JH, et al. The impact of lung cancer on survival of idiopathic pulmonary fibrosis. Chest 2015;147(1):157-164 doi: 10.1378/chest.14-0359.

  62. National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365(5):395-409. doi: 10.1056/ NEJMoa1102873.

  63. Savarino E, Carbone R, Marabotto E, et al. Gastrooesophageal reflux and gastric aspiration in idiopathic pulmonary fibrosis patients. Eur Respir J 2013; 42(5):1322-1331. doi: 10.1183/09031936.00101212.

  64. Tobin RW, Pope CE 2nd, Pellegrini CA, Emond MJ, Sillery J, Raghu G. Increased prevalence of gastroesophagealnreflux disease in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998;158(6):1804-1808.

  65. Lee JS, Song JW, Wolters PJ, et al. Bronchoalveolar lavage pepsin in acute exacerbation of idiopathic pulmonary fibrosis. Eur Respir J 2012;39(2):352-358. doi: 10.1183/09031936.00050911.

  66. Noth I, Zangan SM, Soares RV, et al. Prevalence of hiatal hernia by blinded multidetector CT in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2012; 39: 344-5. doi: 10.1183/09031936.00099910

  67. Tcherakian C, Cottin V, Brillet PY, et al. Progression of idiopathic pulmonary fibrosis: lessons from asymmetrical disease. Thorax 2011;66(3):226-231. doi: 10.1136/ thx.2010.137190.

  68. Lee JS, Ryu JH, Elicker BM, et al. Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;184(12):1390-1394. doi: 10.1164/rccm.201101- 0138OC.

  69. Lee JS, Collard HR, Anstrom KJ, et al.; IPFnet Investigators. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir Med 2013;1(5): 369-376. doi: 10.1016/S2213-2600(13)70105-X.

  70. Buendía-Roldan I, Mejía M, Mateos-Toledo H, et al. Valoración de peso corporal de pacientes con enfermedades intersticiales. XXVII Congreso Venezolano de Neumología y Cirugía Torácica. Porlamar, Venezuela, del 8 al 10 de julio de 2014.

  71. Mermigkis C, Bouloukaki I, Antoniou K, et al. Obstructive sleep apnea should be treated in patients with idiopathic pulmonary fibrosis. Sleep Breath 2015; 19(1):385-391. doi: 10.1007/s11325-014-1033-6.

  72. Holland AE, Fiore JF Jr, Bell EC, et al. Dyspnoea and comorbidity contribute to anxiety and depression in interstitial lung disease. Respirology 2014;19(8): 1215- 1221. doi: 10.1111/resp.12360.

  73. Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ. Prednisone, azathriopine and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012;366(21):1968- 1977. doi: 10.1056/NEJMoa1113354.

  74. Idiopathic Pulmonary Fibrosis Clinical Research Network; Martinez FJ, de Andrade JA, Anstrom KJ, King TE Jr, Raghu G. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2014;370(22): 2093- 2101. doi: 10.1056/NEJMoa1401739.

  75. King TE, Bradford WZ, Castro–Bernadini S, et al.; ASCEND study group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2083-2092. doi: 10.1056/NEJMoa1402582.

  76. Richeldi L, Du Bois R, Raghu G, et al.; INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370(22):2071-2082. doi: 10.1056/NEJMoa1402584.

  77. Kistler KD, Nalysnyk L, Rotella P, Esser D. Lung transplantation in idiopathic pulmonary fibrosis: a systemic review of the literature. BMC Pulm Med 2014; 14:139. doi: 10.1186/1471-2466-14-139.

  78. Nici L, ZuWallack R. Pulmonary rehabilitation: today and tomorrow. Breathe 2010;6(4):305-311. Doi: 10.1183/18106838.0604.305.

  79. Ries, AL, Bauldoff, GS, Carlin, BW, et al. Pulmonary Rehabilitation: Joint ACCP/AACVPR Evidence-Based Clinical Practice Guidelines. Chest 2007; 131(5 Suppl):4S-42S.

  80. Nishiyama O, Taniguchi H, Kondoh Y, et al. Dyspnoea at 6-min walk test in idiopathic pulmonary fibrosis: comparison with COPD. Respir Med 2007; 101(4):833-838.

  81. SwigrisJJ, Kuschner WG, Jacobs SS, Wilson SR, Gould MK. Health related quality of life in patients with idiopathic pulmonary fibrosis: a systematic review. Thorax 2005;60(7):588-594.

  82. Blivet S, Philit F, Sab JM, et al. Outcome of patients with idiopathic pulmonary fibrosis admitted to the ICU for respiratory failure. Chest 2001;120(1):209-212.

  83. Fumeaux T, Rothmeier C, Jolliet P. Outcome of mechanical ventilation for acute respiratory failure in patients with pulmonary fibrosis. Intensive Care Med 2001;27(12):1868-1874.

  84. Saydain G, Islam A, Afessa B, Ryu JH, Scott JP, Peters SG. Outcome of patients with idiopathic pulmonary fibrosis admitted to the intensive care unit. Am J Respir Crit Care Med 2002;166(6):839-842.

  85. Al-Hameed FM, Sharma S. Outcome of patients admitted to the intensive care unit for acute exacerbation of idiopathic pulmonary fibrosis. Can Respir J 2004; 11(2):117-122.

  86. Mollica C, Paone G, Conti V, et al. Mechanical ventilation in patient with end-stage idiopathic pulmonary fibrosis. Respiration 2010;79(3):209-215. doi: 10.1159/000225932.

  87. Vianello A, Arcaro G, Battistella L, et al. Noninvasive ventilation in the event of acute respiratory failure in patients with idiopathic pulmonary fibrosis. J Crit Care 2014;29(4):562-567. doi: 10.1016/j.jcrc.2014.03.019.

  88. Braünlich J, Beyer D, Mai D, Hammerschmidt S, Seyfarth HJ, Wirtz H. Effects of nasal high flow on ventilation in volunteers, COPD and idiopathic pulmonary fibrosis patients. Respiration 2013;85(4):319-325. doi: 10.1159/000342027.

  89. Collard HR, King TE Jr, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003;16885):538-542.

  90. Kolb M, Collard HR. Staging of idiopathic pulmonary fibrosis: past, present and future. Eur Respir Rev 2014;23(132):220-224. doi: 10.1183/09059180.00002114.

  91. Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 2012;156(10):684-691. doi: 10.7326/0003-4819-156-10-201205150-00004.

  92. Collard HR, Bradford WZ, Cottin V, et al. A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials. Eur Respir J 2015;46(1):243-249. doi: 10.1183/09031936.00200614.

  93. Corte TJ, Collard H, Wells AU. Idiopathic interstitial pneumonias in 2015: A new era. Respirology 2015;20(5):697- 698. doi: 10.1111/resp.12559.

  94. Casoni GL, Tomassetti S, Cavazza A, et al. Transbronchial lung cryobiopsy in the diagnosis of fibrotic interstitial lung diseases. PLoS One 2014;9(2):e86716. doi: 10.1371/ journal.pone.0086716.

  95. Zhang Y, Kaminski N. Biomarkers in idiopathic pulmonary fibrosis. Curr Opin Pulm Med 2012;18(5):441-446. doi: 10.1097/MCP.0b013e328356d03c.

  96. Loomis-King H, Flaherty KR, Moore BB. Pathogenesis, current treatments and future directions for idiopathic pulmonary fibrosis. Curr Opin Pharmacol 2013;13(3):377-385. doi: 10.1016/j.coph.2013.03.015.



>Revistas >NCT Neumología y Cirugía de Tórax >Año2016, No. 1
 

· Indice de Publicaciones 
· ligas de Interes 
       
Derechos Resevados 2007